ecancer

Nivolumab with peptide vaccine in patients naive to or that failed ipilimumab

Dr Jeffrey Weber - Moffitt Cancer Center, Tampa, USA

3 Jun 2013

Nivolumab blocking PD1 in lung cancer and melanoma

Dr Suzanne Topalian - Johns Hopkins Medical Center, Baltimore, USA

3 Jun 2013

Selumetinib, the first effective drug for advanced melanoma of the eye

Dr Richard Carvajal - Memorial Sloan Kettering Cancer Center, New York, USA

3 Jun 2013

Ipilimumab and BRAF inhibitors for advanced melanoma

Dr Lynn Schuchter - University of Pennsylvania, USA

2 Jun 2013

PDL1 inhibitors in melanoma

Dr Roy Herbst - Yale Cancer Center, New Haven, USA

2 Jun 2013

Comment on drug developments in advanced melanoma

Dr Roy Herbst - Yale Cancer Center, New Haven, USA

2 Jun 2013

Nivolumab produces long-lasting responses in patients with stage IV melanoma

Dr Mario Sznol - Yale Cancer Center, New Haven, USA

1 Jun 2013

New MEK inhibitor selumetinib is the first effective drug for advanced melanoma of the eye

Dr Richard D. Carvajal - Memorial Sloan-Kettering Cancer Center, New York, USA

1 Jun 2013

Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma

Dr Mario Sznol - Yale Cancer Center New Haven, USA

1 Jun 2013

Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

1 Jun 2013

Prevention of squamous cell carcinoma

Dr Kenneth Tsai - MD Anderson Cancer Center, Houston, USA

23 Apr 2013

Immunotherapy in melanoma and other cancers

Dr Suzanne Topalian – Johns Hopkins, Baltimore, USA

19 Apr 2013

More from ecancer